Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.37 |
| ▸ | PPID | Q08752 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23677261 | 0.79 | GRM4 (0.51) | GRM4LRRK2CA1CA2CA9 | |
| SCHEMBL21337424 | 0.77 | GRM4 (0.40) | GRM4KCNH2ENPP1CA9 | |
| SCHEMBL22350418 | 0.75 | GRM4 (0.39) | GRM4KCNH2ENPP1CA9 | |
| SCHEMBL22350420 | 0.75 | GRM4 (0.39) | GRM4KCNH2ENPP1CA9 | |
| SCHEMBL22350536 | 0.75 | GRM4 (0.39) | GRM4KCNH2ENPP1CA9 | |
| SCHEMBL22350416 | 0.75 | GRM4 (0.39) | GRM4KCNH2ENPP1CA9 | |
| SCHEMBL22350290 | 0.74 | GRM4 (0.37) | GRM4KCNH2ENPP1CA9 | |
| SCHEMBL22350289 | 0.74 | GRM4 (0.37) | GRM4KCNH2ENPP1CA9 | |
| SCHEMBL21623540 | 0.71 | CYP1A2 (0.65) | GRM4KCNH2LRRK2ENPP1CA1 | |
| SCHEMBL21623212 | 0.69 | GRM4 (0.49) | GRM4KCNH2CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3317286-B1 | CYCLIZED SULFAMOYLARYLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2019-09-11 | — | — | EP | disclosed |